Why can't I get Wegovy in Australia right now?
Wegovy has been on the TGA medicine shortages list since launch and supply is intermittent across all dose strengths in April 2026. Novo Nordisk Australia has flagged the constraint publicly. Regional pharmacies sometimes have stock when metro Sydney and Melbourne do not. Mounjaro (tirzepatide) is a real alternative.
Last reviewed · Panya.health editorial
The current state by city
April 2026 reality: Sydney and Melbourne metro pharmacies typically tell patients 'on order, no ETA' across the 0.25, 0.5, 1.0, and 1.7 mg doses. Brisbane and Perth fluctuate week to week. Regional pharmacies in NSW, VIC, QLD, and WA sometimes hold stock for two to three weeks before the next allocation cycle. The TGA medicine shortages register lists Wegovy as a current shortage and Novo Nordisk Australia has flagged ongoing supply constraints publicly. Panya's supply tracker shows the live state per region.
Why the shortage exists
Two compounding causes. Global Wegovy demand outstripped Novo Nordisk's API and pen-fill capacity from 2023 onward; Denmark and the US absorb most of the production. Second, Australian PBS listing rules and pricing leverage mean Australia gets allocated late in the global queue. The TGA approved Mounjaro in late 2024 and that has absorbed some of the diverted demand, which is why Mounjaro stock is more reliable than Wegovy in most pharmacies right now.
What to do instead
Three realistic options. First, switch to Mounjaro: tirzepatide stock in Australia has been markedly more reliable in 2025 to 2026 and the SURMOUNT-1 outcomes are better than the Wegovy comparator. Second, ring regional pharmacies on a Tuesday or Wednesday after the weekly allocation lands; some hold stock for several weeks. Third, accept that the dose hop on resumption may need re-titration if you have been off Wegovy more than four weeks. Do not chase grey-market sources.
Related posts
Tirzepatide monthly cost across 10 markets: US brand, US compounded, UK private, Scandinavia, Germany, Thailand clinic, Thailand direct, Japan, Singapore, Australia. The real numbers, updated April 20...
The three GLP-1 drugs that matter in 2026: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (Lilly's triple-agonist). How they differ in mechanism, weight loss, side effe...
Same drug class, different receptor profile. Here is the honest comparison, without the marketing gloss.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.